Medicare does not cover Osteoboost. The FDA-cleared vibration belt for postmenopausal bone loss is a self-pay device priced at $995, and neither Medicare nor private insurance currently reimburses for it. With a valid prescription, the purchase is eligible for reimbursement through a Health Savings Account or Flexible Spending Account.1Osteoboost. Osteoboost FAQ
Why Medicare Will Not Pay for It
FDA clearance and Medicare coverage are separate decisions on separate timelines. Osteoboost received FDA clearance in January 2024 through the De Novo pathway, which is used for novel devices without a direct predecessor on the market.2FDA. Osteoboost Belt De Novo Authorization (DEN230015) CMS runs its own “reasonable and necessary” review afterward, and that review tends to be slow. A study of 64 novel medical technologies authorized by the FDA between 2016 and 2019 found that the median time to achieve even nominal Medicare coverage was 5.7 years, and only 44 percent reached coverage at all during the follow-up window. Smaller manufacturers fared worse than large ones.3PubMed Central. Time to Medicare Coverage for Novel Medical Technologies
There is also a category problem. Medicare’s existing coverage for bone-stimulation devices (osteogenesis stimulators) is limited to treating nonunion fractures and failed spinal fusions, not low bone density.4CMS. LCD for Osteogenesis Stimulators (L33796) And a separate CMS policy classifies vibration therapy devices as “massage modalities” that are “primarily and customarily used for a nonmedical purpose,” making them ineligible for payment as durable medical equipment.5Noridian Healthcare Solutions. Correct Coding for Vibration Therapy Devices That guidance was last updated in 2018, before Osteoboost existed as a cleared device, so it does not name the product. But there is no existing Medicare benefit category that fits a wearable vibration belt prescribed for osteopenia.
Could That Change Soon
Probably not in the near term. CMS has been trying to shorten the lag between FDA clearance and Medicare payment for breakthrough-designated devices. The agency finalized the Transitional Coverage for Emerging Technologies (TCET) pathway in 2024, then paused it to focus on a successor announced in April 2026, the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway, which aims to deliver a national coverage determination within 60 to 90 days of FDA approval.6Healthcare Dive. CMS, FDA Unveil Speedier Medicare Coverage Pathway for Breakthrough Devices
Osteoboost holds breakthrough designation, which it received in 2020.7National Institute on Aging. NIA Small Business Showcase: Bone Health Technologies To qualify for RAPID, however, a Class II device would need to participate in the FDA’s Total Product Life Cycle Advisory Program and run an active investigational device exemption study enrolling Medicare beneficiaries, with outcomes agreed to by both CMS and the FDA.8CMS. CMS, FDA Announce RAPID Coverage Pathway There is no public indication Osteoboost has applied for or been accepted into RAPID. The manufacturer’s own FAQ says the insurance and Medicare review process “can take several years,” with no specific date for coverage.1Osteoboost. Osteoboost FAQ
What You Will Pay and How to Buy It
Osteoboost currently sells for $995, a promotional launch price below its listed retail price of $1,500.9Osteoboost. Osteoboost Product Page Because it is a prescription device, it qualifies for reimbursement through HSA and FSA accounts when the purchaser has a valid prescription.1Osteoboost. Osteoboost FAQ
You can get the prescription two ways. Your own doctor can write one, or you can use Osteoboost’s telehealth partner, Beluga Health, which charges a $30 fee and does not require an appointment or video visit.10MelioGuide. Osteoboost Review The device ships from a partner pharmacy, Health Warehouse, though the company has reported an 8-to-12-week backorder because of high demand.11Osteoboost. Talk to Your Doctor
Who the Device Is Cleared For
Before paying out of pocket, confirm you fit the cleared population. The FDA cleared Osteoboost specifically for postmenopausal women diagnosed with osteopenia of the lumbar vertebrae or total hip, defined as a bone mineral density T-score between -1.0 and -2.49 on a DXA scan.2FDA. Osteoboost Belt De Novo Authorization (DEN230015) The device has not been tested in women with full osteoporosis, in men, or in premenopausal women. The pivotal 12-month trial behind the clearance did not meet its primary endpoint across the full study population; a statistically significant benefit appeared only in a subgroup who used the belt at least three times per week, and fracture risk was not measured.12JBMR Plus. Benefits of Targeted Vibration for Bone Strength and Bone Density in Postmenopausal Women With Osteopenia
What Medicare Does Cover for Bone Loss
Osteoboost is uncovered, but Medicare pays for several other osteoporosis-related services:
- Bone density screening. Medicare Part B covers a DXA scan once every two years for eligible beneficiaries, and more frequently if medically necessary.13Medicare.gov. Does Medicare Cover Osteoporosis Treatment
- Injectable osteoporosis drugs. Part B covers injectables such as denosumab (Prolia) and zoledronic acid (Reclast) for women who have osteoporosis, meet home health criteria, and have had an osteoporosis-related fracture. Part B typically pays 80 percent after the deductible.14Medicare.gov. Osteoporosis Drugs
- Oral osteoporosis medications. Bisphosphonates and other self-administered drugs are covered under Medicare Part D prescription drug plans.15Medigap.com. Medicare Coverage for Osteoporosis
- Physical therapy. Covered under Part B when medically necessary and ordered by a physician.15Medigap.com. Medicare Coverage for Osteoporosis
These covered options are aimed at patients who have already progressed to osteoporosis or fracture. Osteoboost targets an earlier stage of bone loss, where standard care is often limited to lifestyle changes and monitoring. If you want to use the belt at that stage, expect to pay for it yourself, with HSA or FSA dollars the only form of help currently available.